Modified vaccinia virus Ankara multiplies in the rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines

Journal of General Virology

Volumn 87, Issue 1, 2006, Pages 21-27

  Okeke, Malachy Ifeanyi ^a   Nilssen, Øivind ^b   Traavik, Terje ^a,c  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c GENOK Norwegian Institute of Gene Oncology   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINIA VACCINE;

ANIMAL CELL; ARTICLE; CELL LINE; CELL STRAIN BHK; CHICKEN; CONTROLLED STUDY; FIBROBLAST; HUMAN; MAMMAL CELL; MODIFIED VACCINIA ANKARA VIRUS; NONHUMAN; PRIORITY JOURNAL; RAT; VACCINIA; VACCINIA VIRUS; VERO CELL; VIRION; VIROGENESIS; VIRUS MORPHOGENESIS; VIRUS RECOMBINANT;

ANIMALS; CELL LINE; CELL LINE, TRANSFORMED; CERCOPITHECUS AETHIOPS; CRICETINAE; DNA, VIRAL; KIDNEY; RATS; VACCINIA VIRUS; VERO CELLS; VIRION; VIRUS REPLICATION;

ANIMALIA; ANKARA; CRICETINAE; MAMMALIA; VACCINIA VIRUS;

EID: 30344450083     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.81479-0     Document Type: Article

References (37)

1. Ali, A. N., Turner, P. C., Brooks, M. A. & Moyer, R. W. (1994). The SPI-1 gene of rabbitpox virus determines host range and is required for hemorrhagic pock formation. Virology 202, 305-314.
2. Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. (1998). The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365-396.
3. Beattie, E., Kauffman, E. B., Martinez, H., Perkus, M. E., Jacobs, B. L., Paoletti, E. & Tartaglia, J. (1996). Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes 12, 89-94.
4. Blanchard, T. J., Alcami, A., Andrea, P. & Smith, G. L. (1998). Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79, 1159-1167.
5. Caroll, M. W. & Moss, B. (1997). Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238, 198-211.
6. Carter, G. C., Law, M., Hollinshead, M. & Smith, G. L. (2005). Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. J Gen Virol 86, 1279-1290.
7. Corona Gutierrez, C. M., Tinoco, A., Lopez Contreras, M., Navarro, T., Calzado, P., Vargas, L., Reyes, L., Posternak, R. & Rosales, R. (2002). Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. Hum Gene Ther 13, 1127-1140.
8. Drexler, I., Heller, K., Wahren, B., Erfle, V. & Sutter, G. (1998). Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79, 347-352.
9. Drexler, I., Staib, C. & Sutter, G. (2004). Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 15, 506-512.
10. Gallego-Gomez, J. C., Risco, C., Rodriguez, D., Cabezas, P., Guerra, S., Carrascosa, J. L. & Esteban, M. (2003). Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. J Virol 77, 10606-10622.
11. Gillard, S., Spehner, D. & Drillien, R. (1985). Mapping of a vaccinia virus host range sequence by insertion into the viral thymidine kinase gene. J Virol 53, 316-318.
12. Hanke, T., McMichael, A. J., Dennis, M. J., Sharpe, S. A., Powell, L. A., McLoughlin, L. & Crome, S. J. (2005). Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 23, 1507-1514.
13. Hansen, H., Okeke, M. I., Nilssen, Ø. & Traavik, T. (2004). Recombinant viruses obtained from co-infection in vitro with a live vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus display different plaque phenotypes and loss of the transgene. Vaccine 23, 499-506.
14. Hollinshead, M., Rodger, G., van Eijl, H., Law, M., Hollinshead, R., Vaux, D. J. & Smith, G. L. (2001). Vaccinia virus utilizes microtubules for movement to the cell surface. J Cell Biol 154, 389-402.
15. Hornemann, S., Harlin, O., Staib, C., Kisling, S., Erfle, V., Kaspers, B., Hacker, G. & Sutter, G. (2003). Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J Virol 77, 8394-8407.
16. Krijnse-Locker, J., Kuehn, A., Schleich, S., Rutter, G., Hohenberg, H., Wepf, R. & Griffiths, G. (2000). Entry of the two infectious forms of vaccinia virus at the plasma membrane is signaling-dependent for the IMV but not the EEV. Mol Biol Cell 11, 2497-2511.
17. McKelvey, T. A., Andrews, S. C., Miller, S. E., Ray, C. A. & Pickup, D. J. (2002). Identification of the orthopoxvirus p4c gene, which encodes a structural protein that directs intracellular mature virus particles into A-type inclusions. J Virol 76, 11216-11225.
18. Meiser, A., Boulanger, D., Sutter, G. & Krijnse-Locker, J. (2003a). Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus release. J Gen Virol 84, 1383-1392.
19. Meiser, A., Sancho, C. & Krijnse-Locker, J. (2003b). Plasma membrane budding as an alternative release mechanism of the extracellular enveloped form of vaccinia virus from HeLa cells. J Virol 77, 9931-9942.
20. Meyer, H., Sutter, G. & Mayr, A. (1991). Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72, 1031-1038.
21. Perkus, M. E., Goebel, S. J., Davis, S. W., Johnson, G. P., Limbach, K., Norton, E. K. & Paoletti, E. (1990). Vaccinia virus host range genes. Virology 179, 276-286.
22. Quaroni, A., Wands, J., Trelstad, R. L. & Isselbacher, K. J. (1979). Epithelioid cell cultures from rat small intestine. Characterization by morphologic and immunologic criteria. J Cell Biol 80, 248-265.
23. Ramirez, J. C., Finke, D., Esteban, M., Kraehenbuhl, J. P. & Acha-Orbea, H. (2003). Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol 148, 827-839.
24. Risco, C., Rodriguez, J. R., Lopez-Iglesias, C., Carrascosa, J. L., Esteban, M. & Rodriguez, D. (2002). Endoplasmic reticulum-Golgi intermediate compartment membranes and vimentin filaments participate in vaccinia virus assembly. J Virol 76, 1839-1855.
25. Sancho, M. C., Schleich, S., Griffiths, G. & Krijnse-Locker, J. (2002). The block in assembly of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus morphogenesis. J Virol 76, 8318-8334.
26. Schmelz, M., Sodeik, B., Ericsson, M., Wolffe, E., Shida, H., Hiller, G. & Griffiths, G. (1994). Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J Virol 68, 130-147.
27. Smith, G. L. & Law, M. (2004). The exit of vaccinia virus from infected cells. Virus Res 106, 189-197.
28. Smith, C. L., Dunbar, P. R., Mirza, F. & 9 other authors (2005). Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 113, 259-266.
29. Sodeik, B. & Krijnse-Locker, J. (2002). Assembly of vaccinia virus revisited: de novo membrane synthesis or acquisition from the host? Trends Microbiol 10, 15-24.
30. Spehner, D., Drillien, R., Proamer, F., Houssais-Pecheur, C., Zanta, M.-A., Geist, M., Dott, K. & Balloul, J.-M. (2000). Enveloped virus is the major virus form produced during productive infection with modified vaccinia virus Ankara strain. Virology 273, 9-15.
31. Stittelaar, K. J., Kuiken, T., de Swart, R. L. & 8 other authors (2001). Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19, 3700-3709.
32. Sutter, G., Wyatt, L. S., Foley, P. L., Bennink, J. R. & Moss, B. (1994). A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12, 1032-1040.
33. Tooze, J., Hollinshead, M., Reis, B., Radsak, K. & Kern, H. (1993). Progeny vaccinia and human cytomegalovirus particles utilize early endosomal cisternae for their envelopes. Eur J Cell Biol 60, 163-178.
34. Wang, Z., Chen, W.-W., Li, R.-R., Wen, B. & Sun, J.-B. (2003). Effect of gastrin on differentiation of rat intestinal epithelial cells in vitro. World J Gastroenterol 9, 1786-1790.
35. Weingart, H., Czub, M., Czub, S. & 18 other authors (2004). Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 78, 12672-12676.
36. Wood, S. R., Zhao, Q., Smith, L. H. & Daniels, C. K. (2003). Altered morphology in cultured rat intestinal epithelial IEC-6 cells is associated with alkaline phosphatase expression. Tissue Cell 35, 47-58.
37. Wyatt, L. S., Earl, P. L., Eller, L. A. & Moss, B. (2004). Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A 101, 4590-4595.